Figure INF-9. Prevalence of markers of HBV infection estimated among injecting drug users — studies with national and subnational coverage [see all figures in this series...]

Part (i) Percentage ever infected (positive for aHBc), 2008 to 2009

Notes:

Dark squares are samples with national coverage; blue triangle are samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Italy and Austria are not prevalence of aHBc but prevalence of 'all HBV markers' as a proxy of aHBc prevalence.

Data for Italy include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

Data for Sweden are prevalence of aHBc, aHBs and HBsAg.

Data for Belgium, Italy, Malta, Slovenia and Slovakia is limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

 

Related links:

Statistical bulletin 2010: Figure INF-09 part (i)

For primary sources, study details and data before 2008, see Table INF-115 and Table INF-0.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page

Sources:

Reitox national focal points